Clinical Trial Update: Assess the Oral Bioavailability of New ABT-263 Formulations [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing oral bioavailability of new ABT-263 formulations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Navitoclax (navitoclax)

Snippet

Sponsor: Abbott | Conditions: Chronic Lymphocytic Leukemia, Lymphomas | Phase 1 | Status: COMPLETED